Racura Oncology Seeks ASX Quotation for Additional Ordinary Shares

Race Oncology Ltd. ( (AU:RAC) ) has provided an update.

Racura Oncology Ltd has applied to the ASX for quotation of 66,399 new ordinary fully paid shares under its existing ticker RAC, following the exercise or conversion of options or other convertible securities. The additional shares modestly increase the company’s issued capital base and free float, supporting liquidity in its stock while reflecting ongoing participation by holders of its convertible instruments.

The move signals continued engagement from investors willing to convert into equity, which may be interpreted as confidence in the company’s prospects in the oncology space. For existing shareholders, the issuance introduces a small degree of dilution but also potentially enhances trading depth and visibility of Racura Oncology’s shares on the ASX.

The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.

More about Race Oncology Ltd.

Racura Oncology Ltd is an Australia-listed biotechnology company focused on oncology, with its ordinary fully paid shares traded on the ASX under the code RAC. The company operates in the cancer therapeutics sector and raises capital and manages ownership structure through listed equity securities on the Australian market.

Average Trading Volume: 163,333

Technical Sentiment Signal: Buy

Current Market Cap: A$392.6M

Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.